Immunoassay for Neurological Biomarkers Market Size, Share and Growth Outlook, 2026

Immunoassay for Neurological Biomarkers Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Immunoassay for Neurological Biomarkers Market size is forecast to increase from $1.41 Billion in 2026 to $2.75 Billion in 2034 at a CAGR of 8.7% between 2026 and 2034.

The Immunoassay for Neurological Biomarkers market report provides detailed analysis and outlook of Immunoassay for Neurological Biomarkers segments including By Product Type (Reagents & Kits, Instruments, Services & Software), By Technology (Enzyme-Linked Immunosorbent Assay, Chemiluminescence Immunoassay, Multiplex Assays, Single Molecule Detection ), By Biomarker Type (Amyloid-Beta, Tau Proteins, Neurofilament Light Chain, Alpha-Synuclein, Glial Fibrillary Acidic Protein ), By Application (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Traumatic Brain Injury ), By End-User (Diagnostic Laboratories, Biopharmaceutical Companies, Research Institutes) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Immunoassay for Neurological Biomarkers Industry Overview

Blood-Based Alzheimer’s Disease Biomarkers Expand Diagnostic Accessibility

The immunoassay for neurological biomarkers industry is experiencing significant advancement as blood-based diagnostic technologies become increasingly important in the early detection and management of neurodegenerative diseases. Healthcare providers are seeking less invasive alternatives to traditional diagnostic methods that rely on cerebrospinal fluid analysis and advanced imaging procedures. Roche, in collaboration with Eli Lilly and Company, obtained CE Mark approval for the Elecsys® plasma phosphorylated-tau 217 immunoassay. The assay measures pTau217 concentrations in human plasma to identify amyloid pathology associated with Alzheimer’s disease. By operating on Roche’s established automated laboratory instrument base, the test enables high-throughput screening of symptomatic patients and facilitates earlier clinical assessment. The availability of blood-based neurological biomarker testing is helping expand access to precision diagnostics while reducing dependence on invasive and resource-intensive diagnostic procedures.

Genetic Risk Assessment Supports Personalized Neurological Treatment Strategies

Precision medicine is becoming a central component of the neurological biomarker testing landscape as clinicians increasingly require genetic information to guide therapeutic decision-making. Roche further expanded its neurology diagnostics portfolio with CE Mark authorization for the Elecsys® Apolipoprotein E4 biomarker test, the first in vitro diagnostic immunoassay capable of identifying ApoE4 carrier status directly from a blood sample. The assay is clinically validated for adults experiencing cognitive decline and plays an important role in evaluating patient suitability for disease-modifying therapies targeting Alzheimer’s disease. Determining ApoE4 status enables physicians to assess the risk of Amyloid-Related Imaging Abnormalities before initiating anti-amyloid monoclonal antibody treatments. The growing use of biomarker-guided patient stratification highlights the industry's transition toward personalized neurological care and targeted therapeutic interventions.

Advanced Tau Biomarkers Accelerate Neurodegenerative Disease Research

Research applications continue to drive innovation within the immunoassay for neurological biomarkers industry as pharmaceutical companies seek more precise tools to evaluate disease progression and therapeutic response. Beckman Coulter Diagnostics introduced its fully automated Brain-Derived Tau Research Use Only immunoassay, designed to selectively measure central nervous system-derived tau proteins while minimizing interference from peripheral tau sources. Built on the company’s automated clinical testing infrastructure, the assay provides researchers with a highly specific blood-based biomarker for monitoring neuronal injury and neurodegenerative disease activity. The ability to accurately quantify brain-derived tau proteins supports drug discovery programs, biomarker validation studies, and clinical research focused on Alzheimer’s disease and other neurological disorders. As the demand for objective and scalable neurological biomarkers continues to increase, advanced immunoassay technologies are becoming essential tools for translational research and next-generation therapeutic development.

Immunoassay for Neurological Biomarkers Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Immunoassay for Neurological Biomarkers market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Quanterix Corporation, Thermo Fisher Scientific Inc. (Olink Proteomics), Abbott Laboratories, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Merck KGaA (MilliporeSigma), QIAGEN N.V., Fujirebio (Miraca Holdings Inc.), C2N Diagnostics, LLC, Randox Laboratories Ltd., Autobio Diagnostics. The Immunoassay for Neurological Biomarkers market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Immunoassay for Neurological Biomarkers industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Immunoassay for Neurological Biomarkers Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Immunoassay for Neurological Biomarkers companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Immunoassay for Neurological Biomarkers markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Immunoassay for Neurological Biomarkers Market Competitive Benchmarking and Company Analysis

Leading companies in Immunoassay for Neurological Biomarkers industry include- Quanterix Corporation, Thermo Fisher Scientific Inc. (Olink Proteomics), Abbott Laboratories, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Merck KGaA (MilliporeSigma), QIAGEN N.V., Fujirebio (Miraca Holdings Inc.), C2N Diagnostics, LLC, Randox Laboratories Ltd., Autobio Diagnostics. The Immunoassay for Neurological Biomarkers market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Immunoassay for Neurological Biomarkers Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Immunoassay for Neurological Biomarkers market remains one of the strongest-performing segments in the country.
The US Immunoassay for Neurological Biomarkers Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Immunoassay for Neurological Biomarkers market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Immunoassay for Neurological Biomarkers industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Immunoassay for Neurological Biomarkers markets

Canada's strong Immunoassay for Neurological Biomarkers sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Immunoassay for Neurological Biomarkers market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Immunoassay for Neurological Biomarkers Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Immunoassay for Neurological Biomarkers market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Immunoassay for Neurological Biomarkers population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Immunoassay for Neurological Biomarkers industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Immunoassay for Neurological Biomarkers market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Immunoassay for Neurological Biomarkers sales through 2034

France Immunoassay for Neurological Biomarkers companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Immunoassay for Neurological Biomarkers Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Immunoassay for Neurological Biomarkers distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Immunoassay for Neurological Biomarkers Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Immunoassay for Neurological Biomarkers market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Immunoassay for Neurological Biomarkers industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Immunoassay for Neurological Biomarkers industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Immunoassay for Neurological Biomarkers Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Immunoassay for Neurological Biomarkers market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Immunoassay for Neurological Biomarkers market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Immunoassay for Neurological Biomarkers Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Immunoassay for Neurological Biomarkers Market Segmentation

By Product Type
Reagents & Kits
Instruments
Services & Software
By Technology
Enzyme-Linked Immunosorbent Assay
Chemiluminescence Immunoassay
Multiplex Assays
Single Molecule Detection
By Biomarker Type
Amyloid-Beta
Tau Proteins
Neurofilament Light Chain
Alpha-Synuclein
Glial Fibrillary Acidic Protein
By Application
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Traumatic Brain Injury
By End-User
Diagnostic Laboratories
Biopharmaceutical Companies
Research Institutes

Top Companies in Immunoassay for Neurological Biomarkers Industry

Quanterix Corporation
Thermo Fisher Scientific Inc. (Olink Proteomics)
Abbott Laboratories
F. Hoffmann-La Roche Ltd
Bio-Rad Laboratories, Inc.
Merck KGaA (MilliporeSigma)
QIAGEN N.V.
Fujirebio (Miraca Holdings Inc.)
C2N Diagnostics, LLC
Randox Laboratories Ltd.
Autobio Diagnostics

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Biotech and Fermented Ingredient Integration to gain rapid penetration

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025